Cargando…

Population Pharmacokinetic and Exposure–Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease

BACKGROUND: Finerenone (BAY 94-8862) is a potent non-steroidal, selective mineralocorticoid receptor antagonist being developed for the treatment of patients with type 2 diabetes and chronic kidney disease. METHODS: We present the population pharmacokinetics and pharmacodynamics (PD) analysis for ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Snelder, Nelleke, Heinig, Roland, Drenth, Henk-Jan, Joseph, Amer, Kolkhof, Peter, Lippert, Jörg, Garmann, Dirk, Ploeger, Bart, Eissing, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051931/ https://www.ncbi.nlm.nih.gov/pubmed/31583611 http://dx.doi.org/10.1007/s40262-019-00820-x

Ejemplares similares

Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis
por: van den Berg, Paul, et al.
Publicado: (2021)

Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria
por: Goulooze, Sebastiaan Camiel, et al.
Publicado: (2021)

The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
por: Heinig, Roland, et al.
Publicado: (2023)

Dose–Exposure–Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD
por: Goulooze, Sebastiaan Camiel, et al.
Publicado: (2022)

Physiologically‐based pharmacokinetic modeling to predict CYP3A4‐mediated drug‐drug interactions of finerenone
por: Wendl, Thomas, et al.
Publicado: (2021)

NT‐proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure
por: Schmitt, Walter, et al.
Publicado: (2021)

Characterisation of the pharmacokinetics of ethinylestradiol and drospirenone in extended-cycle regimens: population pharmacokinetic analysis from a randomised Phase III study
por: Reif, Stefanie, et al.
Publicado: (2013)

Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
por: Filippatos, Gerasimos, et al.
Publicado: (2020)

Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes
por: Agarwal, Rajiv, et al.
Publicado: (2023)

Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone—Translational Aspects and Clinical Perspectives across Multiple Organ Systems
por: Kolkhof, Peter, et al.
Publicado: (2022)

Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone
por: Agarwal, Rajiv, et al.
Publicado: (2020)

Population pharmacokinetics of regorafenib in solid tumours: Exposure in clinical practice considering enterohepatic circulation and food intake
por: Keunecke, Anne, et al.
Publicado: (2020)

Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
por: Agarwal, Rajiv, et al.
Publicado: (2021)

The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury
por: Dutzmann, Jochen, et al.
Publicado: (2017)

Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial
por: Filippatos, Gerasimos, et al.
Publicado: (2021)

Mineralocorticoid receptor antagonism by finerenone is sufficient to improve function in preclinical muscular dystrophy
por: Lowe, Jeovanna, et al.
Publicado: (2020)

Finerenone, a Non-Steroidal Mineralocorticoid Receptor Antagonist, Reduces Vascular Injury and Increases Regulatory T-Cells: Studies in Rodents with Diabetic and Neovascular Retinopathy
por: Jerome, Jack R., et al.
Publicado: (2023)

Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction
por: Lima-Posada, Ixchel, et al.
Publicado: (2023)

Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO‐DKD trial
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice
por: Pieronne‐Deperrois, Marie, et al.
Publicado: (2021)

Results From Drug–Drug Interaction Studies In Vitro and In Vivo Investigating the Inhibitory Effect of Finerenone on the Drug Transporters BCRP, OATP1B1, and OATP1B3
por: Heinig, Roland, et al.
Publicado: (2022)

Physiologically Based Pharmacokinetic Modeling of Tamoxifen and its Metabolites in Women of Different CYP2D6 Phenotypes Provides New Insight into the Tamoxifen Mass Balance
por: Dickschen, Kristin, et al.
Publicado: (2012)

Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress
por: González-Blázquez, Raquel, et al.
Publicado: (2018)

Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD Trials
por: Flack, John M., et al.
Publicado: (2023)

The Role of Finerenone in the Management of Diabetic Nephropathy
por: Veneti, Stavroula, et al.
Publicado: (2021)

Potassium management with finerenone: Practical aspects
por: Wanner, Christoph, et al.
Publicado: (2022)

Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study
por: Ruilope, Luis M, et al.
Publicado: (2022)

Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes
por: Ruilope, Luis M., et al.
Publicado: (2022)

Application of Physiologically‐Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of Moxifloxacin
por: Willmann, Stefan, et al.
Publicado: (2019)

A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim
por: Niederalt, Christoph, et al.
Publicado: (2017)

Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically‐based pharmacokinetic predictions
por: Willmann, Stefan, et al.
Publicado: (2021)

Population pharmacokinetics and pharmacodynamics of a novel vascular adhesion protein-1 inhibitor using a multiple-target mediated drug disposition model
por: Snelder, Nelleke, et al.
Publicado: (2020)

Cardiorenal benefits of finerenone: protecting kidney and heart
por: González-Juanatey, José R., et al.
Publicado: (2023)

Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
por: Shah, Monarch, et al.
Publicado: (2023)

SAT-LB106 Metabolic and Brown Adipose Tissue-Specific Effects of the Novel Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in a Mouse Model of Diet-Induced Obesity
por: Marzolla, Vincenzo, et al.
Publicado: (2020)

A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
por: Filippatos, Gerasimos, et al.
Publicado: (2016)

Enantioselective Total Synthesis of (−)‐Finerenone Using Asymmetric Transfer Hydrogenation
por: Lerchen, Andreas, et al.
Publicado: (2020)

Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone
por: Agarwal, Rajiv, et al.
Publicado: (2023)

Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis
por: Filippatos, Gerasimos, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_eius63qj0a8pqtr60q9amd5ma6